LLY

768.85

+0.75%↑

JNJ

176.51

-0.72%↓

ABBV

220.71

+0.68%↑

UNH

341.39

-0.06%↓

AZN

76.89

-1.07%↓

LLY

768.85

+0.75%↑

JNJ

176.51

-0.72%↓

ABBV

220.71

+0.68%↑

UNH

341.39

-0.06%↓

AZN

76.89

-1.07%↓

LLY

768.85

+0.75%↑

JNJ

176.51

-0.72%↓

ABBV

220.71

+0.68%↑

UNH

341.39

-0.06%↓

AZN

76.89

-1.07%↓

LLY

768.85

+0.75%↑

JNJ

176.51

-0.72%↓

ABBV

220.71

+0.68%↑

UNH

341.39

-0.06%↓

AZN

76.89

-1.07%↓

LLY

768.85

+0.75%↑

JNJ

176.51

-0.72%↓

ABBV

220.71

+0.68%↑

UNH

341.39

-0.06%↓

AZN

76.89

-1.07%↓

Search

Organon & Co

Închisă

SectorSănătate

10.45 1.06

Rezumat

Modificarea prețului

24h

Curent

Minim

10.33

Maxim

10.94

Indicatori cheie

By Trading Economics

Venit

-174M

-87M

Vânzări

81M

1.6B

P/E

Medie Sector

3.866

35.293

EPS

1

Randament dividend

8.08

Marjă de profit

-5.443

Angajați

10,000

EBITDA

124M

449M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+32.72% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

8.08%

3.07%

Următoarele câștiguri

30 oct. 2025

Data viitoare de dividende

11 dec. 2025

Următoarea dată ex-dividende

11 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

190M

2.7B

Deschiderea anterioară

9.39

Închiderea anterioară

10.45

Sentimentul știrilor

By Acuity

50%

50%

167 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Organon & Co Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

17 sept. 2025, 23:01 UTC

Achiziții, Fuziuni, Preluări

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 sept. 2025, 22:48 UTC

Achiziții, Fuziuni, Preluări

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 sept. 2025, 21:59 UTC

Câștiguri

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 sept. 2025, 23:44 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

17 sept. 2025, 23:39 UTC

Market Talk

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 sept. 2025, 22:20 UTC

Achiziții, Fuziuni, Preluări

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 sept. 2025, 22:20 UTC

Achiziții, Fuziuni, Preluări

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 sept. 2025, 22:20 UTC

Achiziții, Fuziuni, Preluări

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 sept. 2025, 22:19 UTC

Achiziții, Fuziuni, Preluări

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 sept. 2025, 22:18 UTC

Achiziții, Fuziuni, Preluări

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 sept. 2025, 21:00 UTC

Câștiguri

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 sept. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

17 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 sept. 2025, 19:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 sept. 2025, 19:59 UTC

Market Talk

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 sept. 2025, 19:07 UTC

Market Talk

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 sept. 2025, 18:43 UTC

Market Talk

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 sept. 2025, 18:38 UTC

Market Talk

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 sept. 2025, 18:20 UTC

Market Talk

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 sept. 2025, 18:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 sept. 2025, 18:18 UTC

Market Talk

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 sept. 2025, 18:14 UTC

Market Talk

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 sept. 2025, 17:59 UTC

Market Talk

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 sept. 2025, 17:15 UTC

Achiziții, Fuziuni, Preluări

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 sept. 2025, 17:06 UTC

Achiziții, Fuziuni, Preluări

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 sept. 2025, 16:51 UTC

Câștiguri

Correct: Exor 1H Net Loss -EUR624M

17 sept. 2025, 16:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 sept. 2025, 16:34 UTC

Market Talk

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 sept. 2025, 16:25 UTC

Câștiguri

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 sept. 2025, 16:23 UTC

Câștiguri

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Comparație

Modificare preț

Organon & Co Așteptări

Obiectiv de preț

By TipRanks

32.72% sus

Prognoză pe 12 luni

Medie 13.75 USD  32.72%

Maxim 18 USD

Minim 9.5 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOrganon & Co - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

1

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

8.53 / 9.18Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

No Evidence

Sentiment

By Acuity

167 / 371 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
help-icon Live chat